Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive. Inv ...

文章核心观点 - 公司已启动针对其主要产品deramiocel的生物制品许可申请(BLA)的滚动提交过程 [1][2] - 该申请可能符合FDA的优先审评资格,因为deramiocel可能为治疗严重的杜氏肌肉营养不良症心肌病提供显著的安全性和/或有效性改善,目前尚无获批的治疗方案 [2] - 公司计划于2024年底前完成BLA的滚动提交 [2] 公司概况 - 公司是一家专注于开发转化性细胞和外泌体治疗方法的生物技术公司 [6] - 公司的主要产品候选药物deramiocel(CAP-1002)是一种同种异体心源性细胞治疗,已在临床前和临床研究中显示出免疫调节、抗纤维化和再生作用 [3] - deramiocel已获得孤儿药物认定,并获得再生医学高级疗法(RMAT)指定,有利于监管路径 [4] - 如果获得FDA批准,公司还有资格获得罕见儿童疾病优先审评券 [4] 杜氏肌肉营养不良症概况 - 杜氏肌肉营养不良症是一种严重的遗传性疾病,导致骨骼、心脏和呼吸肌肉逐渐虚弱和慢性炎症,中位寿命约30岁 [5] - 该病在美国的患病人群估计为15,000-20,000人 [5] - 该病的发病机制是由于功能性肌肉蛋白distrophin的生产受损,导致肌肉细胞受损和纤维化 [5] - 目前治疗选择有限,尚无治愈方法 [5]

Capricor Therapeutics (CAPR) closed the last trading session at $18.09, gaining 330.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $34.40 indicates a 90.2% upside potential. The average comprises five short-term price targets ranging from a low of $25 to a high of $43, with a standard deviation of $8.71. While the lowest estimate indicates an increase of 38.2% from the current ...

Capricor Therapeutics Inc. CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year. The medical sector company plans to file the biologics license application (BLA) in October 2024, seeking full FDA approval to treat all patients with cardiomyopathy associated with DMD. This rare ...

Capricor Therapeutics Inc. NASDAQ: CAPR is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like Duchenne muscular dystrophy (DMD). Capricor's stock surged more than 100% after announcing it will pursue full FDA approval for its primary drug deramiocel (CAP-1002) in this year. The medical sector company plans to file the biologics license application (BLA) in October 2024, seeking full FDA approval to treat all patients with cardiomyopathy associated with DMD. C ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Capricor Therapeutics (CAPR) shares rallied 18.2% in the last trading session to close at $5.97. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 10.8% gain over the past four weeks. The sharp upsurge in Capricor's shares can be attributed to the company's anticipated regulatory update on deramiocel for Duchenne muscular dystrophy (DMD) in an investor webcast scheduled for Sept. 24. The webcast will include th ...

SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will host an investor webcast on Tuesday, September 24, 2024 at 8:30 a.m. ET to provide an update on its Duchenne muscular dystrophy (DMD) program. The update will consist of the latest regulatory updates following the Company's recent meetings with the U.S. Food and Drug Administr ...

-Capricor to Receive $15 Million Equity Investment at a 20% Premium, as well as $20 Million Upfront Payment upon Signing Definitive Agreement with up to $715 Million in Potential Milestones and a DoubleDigit Percentage of Product Revenue- -Upfront Payment and Investment Extends Cash Runway into 2026- -Potential Milestones from Combined Distribution Agreements Now Total approximately $1.5 Billion- -Capricor Preparing to Meet with EMA to Discuss European Expansion for Deramiocel- SAN DIEGO, Sept. 17, 2024 (GL ...

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is scheduled to present at various upcoming investor and scientific conferences. Capricor management will present updates on Capricor's recent progress on its lead program of deramiocel for the treatment of Duchenne muscular dystrophy (DMD) as well as other general scienti ...